Search results
Results from the WOW.Com Content Network
With Johnson & Johnson behind it, and with an additional $100 million invested in its development, the Palmaz stent was approved for use in peripheral arteries in 1991, followed by approval for use in coronary arteries in 1994; Johnson & Johnson quickly captured 90 percent of the market for stents and bought the patent outright from Palmaz ...
Stent technology improved rapidly, and in 1989 the Palmaz-Schatz balloon-expandable intracoronary stent was developed. [24] [25] Initial results with the Palmaz-Schatz stents were excellent when compared to balloon angioplasty, with a significantly lower incidence of abrupt closure and peri-procedure heart attack. [26]
Though several doctors have been credited with the creation of the stent, the first FDA-approved stent in the U.S. was created by Richard Schatz and coworkers. Named the Palmaz-Schatz (Johnson & Johnson), it was developed in 1987. [21] To further reduce the incidence of restenosis, the drug-eluting stent was introduced in 2003. [22]
During a balloon angioplasty, the stent is inserted into the artery to provide a "scaffold" to open the artery. An anti-rejection-type medication, sirolimus , helps to limit the overgrowth of normal cells while the artery heals which reduces the chance of re-blockage in the treated area known as restenosis , and reduces the chances that another ...
To sit in the back of the room watching the impeccably dressed, articulate men and women who are orchestrating Johnson & Johnson’s trailblazing cures for cancer, Alzheimer’s, diabetes, AIDS and mental illness, and to watch the Wall Street crowd digesting it and calculating the potential cash flows and returns on investment, was to watch the free market dream come true.
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. In 2023, the company split-off its consumer healthcare business sector into a new publicly traded company, Kenvue .
Dementia is a devastating condition that impacts up to 10 percent of older adults. And while there's no cure, getting diagnosed early can help patients get on a treatment plan and families prepare ...
The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...